Desloratadine
- Generic Name
- Desloratadine
- Brand Names
- Aerius, Clarinex, Clarinex-D, Neoclarityn, Desloratadine ratiopharm, Desloratadine Teva, Desloratadine Actavis, Dasselta, Azomyr
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19ClN2
- CAS Number
- 100643-71-8
- Unique Ingredient Identifier
- FVF865388R
- Background
Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
- Indication
For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
- Associated Conditions
- Allergic Rhinitis (AR), Asthma, Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Nasal symptoms, Non-nasal symptoms
- Associated Therapies
- Antihistamine
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine
- Conditions
- Allergic Rhinitis
- Interventions
- Drug: Desloratadine / Betamethasone in fixed dose
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 70
- Registration Number
- NCT06916884
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2024-02-22
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- EMS
- Target Recruit Count
- 318
- Registration Number
- NCT06272409
Antiplatelet Therapy in Chronic Urticaria
- Conditions
- Chronic Urticaria
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 12
- Registration Number
- NCT06268470
- Locations
- 🇹🇭
Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
Over-the-Counter Antihistamines & Heat Stress
- Conditions
- Sudomotor Sympathetic DysfunctionHeat IllnessAllergic RhinitisHeat Injury
- Interventions
- Other: Placebo (Sugar Pill)
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Lakehead University
- Target Recruit Count
- 16
- Registration Number
- NCT06217367
- Locations
- 🇨🇦
Lakehead University C.J Sanders Fieldhouse, Thunder Bay, Ontario, Canada
Role of Desloratadine in Reducing Inflammation From Occupational Heat Strain
- Conditions
- Heat Stress, ExertionalInflammatory ResponseFirefighter Personal Protective Equipment
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-07-06
- Lead Sponsor
- University of Victoria
- Target Recruit Count
- 12
- Registration Number
- NCT05446480
- Locations
- 🇨🇦
University of Victoria, Victoria, British Columbia, Canada
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
- Conditions
- Relapsing Multiple SclerosisPrimary Progressive Multiple Sclerosis
- Interventions
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 236
- Registration Number
- NCT05232825
- Locations
- 🇮🇹
IRCCS Istituto Neurologico Neuromed, Pozzilli, Molise, Italy
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇨🇿Fakultni nemocnice u sv. Anny, Brno, Czechia
Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2022-01-31
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Eurofarma Laboratorios S.A.
- Target Recruit Count
- 262
- Registration Number
- NCT05214911
- Locations
- 🇧🇷
Eurofarma Laboratorios S.A, São Paulo, Brazil
Influence of Antipruritics on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
- Conditions
- Pruritus
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 13
- Registration Number
- NCT04399148
- Locations
- 🇧🇪
Center for Clinical Pharmacology, Leuven, Belgium
Influence of H1-antihistamines on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin.
- Conditions
- Pruritus
- Interventions
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2020-05-27
- Lead Sponsor
- Universitaire Ziekenhuizen KU Leuven
- Target Recruit Count
- 12
- Registration Number
- NCT04399525
- Locations
- 🇧🇪
Center for Clinical Pharmacology, Leuven, Belgium
Aprepitant vs. Desloratadine in EGFR-TKIs Related Pruritus Treatment
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 138
- Registration Number
- NCT02646020
- Locations
- 🇨🇳
Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.